P lease implant a defibrillator in my patient, read the letter from the referring physician. "He was resuscitated from a cardiac arrest resulting from ventricular fibrillation. He had no myocardial infarction, and he has no evidence of acute ischemia, although he has extensive inoperable coronary artery disease."
Editorial Implantable Cardioverter-Defibrillator
Lifesaver or a Device Looking for a Disease? Douglas P. Zipes, MD P lease implant a defibrillator in my patient, read the letter from the referring physician. "He was resuscitated from a cardiac arrest resulting from ventricular fibrillation. He had no myocardial infarction, and he has no evidence of acute ischemia, although he has extensive inoperable coronary artery disease."
The implantable cardioverter-defibrillator (ICD) is one of the most revolutionary therapies developed in the past two decades to treat patients with life-threatening ventricular arrhythmias. The device, created in the late 1970s to deliver a shock to tenninate ventricular fibrillation (VF), has evolved into a sophisticated piece of equipment capable of VVI pacing for bradycardias and delivering programmed tiered therapy for ventricular tachyarrhythmias. In response to the patient's rhythm disturbance, the ICD automatically escalates the intensity of treatment from competitive pacing to synchronous cardioversion and then to defibrillation. It The ethics of performing a randomized trial of the ICD have been challenged, much as the ethics of executing the CAST were questioned. This is an important issue and one that the organizers at the National Heart, Lung, and Blood Institute (NHLBI) and the participating investigators have wrestled with at length during the planning stages of the present study. Some would respond that it is unethical not to do such a study. The typical patient who is offered to dispute the ethical propriety is not the one presented in the first paragraph but rather a much younger version who has excellent left ventricular function with minimal coronary disease and has been resuscitated from VF. In that patient, recurrent VF looms front and center as the major risk of death, without competing abnormal hemodynamics, and But do we really? Despite recent reports of superb implantation and short-term follow-up results of the ICD,19 it is important not to lose sight of device complications that can cause discomfort, disability, and, on occasion, even death.20 Citing better survival data for sudden or even total mortality in groups treated with devices15'2' compared with drugs7'8 can be challenged, as noted above, because the populations in the two treatment arms may not be the same.
Until we directly randomize the ICD against the best medical management, we will not know which therapy is best in general or for a specific patient group, eg, those with good left ventricular function22 versus those without. There may be specific groups who benefit from the ICD more than others. But we will not know that without a randomized evaluation. In fact, two studies have done just that, ie, they have randomized the ICD versus amiodarone or 13-adrenoceptor blockers in patients resuscitated from cardiac arrest, VF, or hypotensive VT. In one of them,23 preliminary results on 229 patients show that there is no difference in total mortality between patients receiving amiodarone or metoprolol drug therapy and those receiving an ICD. In the other study,24 recruitment continues after randomization of about 300 patients, presumably because the Data Safety Monitoring Board has found no reason to stop the study, ie, no differences exist in the two therapeutic arms. Amiodarone has been discontinued in 7% of patients, whereas the ICD has been removed without reimplantation in 2%. Eighteen percent of the ICD patients have received amiodarone, whereas 3.5% of amiodarone patients have received an ICD (Stuart Connolly, MD, personal communication).
To answer some of the questions raised above, a prospective, randomized, multicenter trial interpreted on an intention-to-treat basis has been designed. The Antiarrhythmics Versus Implantable Defibrillators (AVID) study, supported by the NHLBI, randomizes to the best drug treatment or an ICD patients resuscitated from VF, sustained VT with syncope, or sustained VT with serious hemodynamic consequences including chest pain, systolic blood pressure <80 mm Hg, or near-syncope and an ejection fraction <0.40. The primary end point is total mortality, with secondary end points of quality of life, cost, surgical morbidity and mortality, adverse drug experiences, and ICD system failure. Other patients whose arrhythmia is judged to be less serious, including those with sustained VT with a systolic blood pressure <80 mm Hg but an ejection fraction >0.40, stable sustained VT, out-of-hospital VT or VF due to a transient or correctable cause, or out-of-hospital unexplained syncope with structural heart disease and VT with symptoms induced at electrophysiological study, will be entered in a registry to judge the adequacy of the population sampling from which the randomized patients are drawn. These patients will be followed up through the National Death Index to allow mortality assessment so that AVID results can be put into proper perspective.
Patients who meet the entry criteria will then be randomized to drug or device. The ICD will be implanted via a nonthoracotomy approach when possible, unless the patient is also undergoing coronary artery bypass surgery. the referring physician believes, the study could be terminated before the end of the recruitment of all the patients in the main study. The goal is to be able to tell this physician confidently that his patient should receive implantation of the ICD or would be better treated with amiodarone or sotalol and to support the decision with believable data. It is toward this level of certainty that we are all striving. Until that time, physicians will continue to have to make therapeutic decisions based on the available published data.
